This study tested the feasibility of conducting a pediatric nutrition-based intervention for youth with migraine that combines biomarker assessment and patient- and caregiver-centered procedures. The trial was a quasi-randomized, double-blind, placebo-controlled feasibility study run at two academic pediatric neurology clinics. Key aims were to evaluate recruitment and retention processes, capacity to collect longitudinal biospecimens using dried blood spot cards, completion of repeated dietary assessments, caregiver-reported supplement adherence, and acceptability of the intervention and study procedures.
Children and adolescents aged 10–17 years with a clinical diagnosis of migraine were assessed for eligibility. Of 58 individuals screened, 57 were enrolled and allocated using sequential alternating assignment to intervention or placebo (29 assigned to omega-3 supplementation; 28 to matched coconut oil placebo). Forty-four participants (77%) completed the planned 12-week follow-up, with 22 completers in each arm. The observed retention met the predefined post-hoc benchmark of at least 70%.
Participants received daily study supplements for 12 weeks. The active supplement provided 850 mg total of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA). The placebo was matched coconut oil. The trial was double-blinded so families and study staff assessing outcomes were not aware of allocation under the sequential alternating allocation scheme used for assignment.
The investigators established post-hoc feasibility benchmarks informed by published pediatric trial literature. Benchmarks included: recruitment greater than 70% of target sample, retention of at least 70%, caregiver-reported supplement adherence of at least 70% (reporting administration on most days), biospecimen completion of at least 90%, dietary recall completion of at least 80%, and favorable acceptability ratings from at least 70% of caregivers. Feasibility outcomes reported here focused on those metrics; clinical efficacy outcomes were stated as to be reported separately.
All participants who attended study visits completed dried blood spot collection at both time points, yielding 100% biospecimen completion among visit attendees. Among study completers, all 44 participants finished the four planned 24-hour dietary recalls (100% completion). These results indicate high feasibility for remote-friendly biospecimen collection and repeated dietary assessment in this pediatric migraine population.
Caregiver exit questionnaires indicated high acceptability of daily supplement administration. The majority of caregivers rated the intervention as acceptable and reported openness to future dietary supplement use for migraine management. Caregiver-reported supplement adherence met the pre-specified benchmark (≥70% reporting administration on most days), although specific adherence percentages were not detailed in this report.
Thirteen participants discontinued before study completion. Reported reasons included five voluntary withdrawals, five lost to follow-up, two who stopped because of supplement palatability concerns, and one participant who no longer met inclusion criteria. Structured telephone follow-up at weeks 4 and 8 was used to support retention and to monitor adherence; these remote contacts were cited as supportive to the overall follow-up completion.
The trial met all six post-hoc feasibility benchmarks. The authors conclude that a pediatric nutrition-based migraine intervention integrating longitudinal lipid biomarker collection via dried blood spot cards, repeated dietary recalls, validated patient-reported outcome measures, and structured remote follow-up is feasible and acceptable to families. Based on these feasibility findings, the investigators recommend progression to a larger-scale randomized controlled trial with protocol modifications that include concealed randomization, prospective daily headache diaries for symptom tracking, and a longer intervention duration. Clinical efficacy outcomes from this feasibility cohort will be reported separately.
The trial is registered on ClinicalTrials.gov (NCT06899074), with registration reported on 20 March 2025. The University of North Carolina institutional review board provided ethical approval. The authors declared no competing interests and stated that study data are available upon reasonable request.